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Abstract
Background: HIV-1 RNA and CD4 cell counts are important parameters for HIV care. The objective of this study was to assess
the overall trends in HIV-1 viral load and CD4 cell counts within our clinic.
Methods: Patients with at least one of each test performed by the Infectious Diseases Laboratory from 1999 through 2011
were included in this analysis. By adapting a novel statistical model, log10 HIV-1 RNA means were estimated by month, and
log10-transformed HIV-1 RNA means were estimated by calendar year. Geometric means were calculated for CD4 cell counts
by month and calendar year. Log10 HIV-1 RNA and CD4 cell count monthly means were also examined with polynomial
regression.
Results: There were 1,814 individuals with approximately 25,000 paired tests over the 13-year observation period. Based on
each patient’s final value of the year, the percentage of patients with viral loads below the lower limit of quantitation rose
from 29% in 1999 to 72% in 2011, while the percentage with CD4 counts ,200 cells/mL fell from 31% to 11%. On average
annually, the mean HIV-1 RNA decreased by 86 copies/mL and the mean CD4 counts increased by 16 cells/mL. For the
monthly means, the correlations (R2) from second-order polynomial regressions were 0.944 for log10 HIV-1 RNA and 0.840
for CD4 cell counts.
Conclusions: Marked improvements in HIV-1 RNA suppression and CD4 cell counts were achieved in a large inner-city
population from 1999 through 2011. This success demonstrates that sustained viral control with improved immunologic
status can be a realistic goal for most individuals in clinical care.
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[13],[14]. In addition, combination antiretroviral therapy regimens have been associated with many adverse side effects
including metabolic changes and drug toxicities [15] as well as
development of drug resistance [16], thus leading to virologic
failure and poor clinical outcomes [17].
In order to respond to these complexities, our medical center’s
Infectious Diseases Clinic has provided HIV and primary care in a
comprehensive model with an on-site, multidisciplinary team of
nurses, physicians, social workers, pharmacists, and medical
subspecialists. In this evaluation, we reviewed the HIV-1 viral
loads and CD4 cell counts from 1999 through 2011 to determine
the overall trends in viral load reduction and immune reconstitution across the entire spectrum of patients receiving HIV
treatment in an inner-city setting. A novel statistical model was
adapted to estimate the HIV-1 RNA values outside of the
quantitative range.

Introduction
Care for HIV-infected patients has changed dramatically over
the last three decades [1] largely due to advances in antiretroviral
therapies, which have allowed improvements in HIV-1 viral loads
and CD4 cell counts. Because of these gains, the life expectancy of
individuals diagnosed with HIV who are able to maintain fully
suppressive antiretroviral regimens, now approaches those without
infection [2]. However, inner-city and veteran populations with
serious co-morbidities can present special challenges to achieving
these gains. These comorbidities [3–6] which often include alcohol
and substance abuse [7–9] and mental illness [10–12] can lead to
concurrent disease manifestations and drug-drug interactions.
Compared to those without infection, HIV-infected patients also
have higher rates of poor treatment adherence due to lack of
family/social support, adverse drug effects, complex drug
regimens, psychological distress, and low patient self-efficacy
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Figure 1. Distribution of final HIV-1 RNA and CD4 cell counts. (A) Final HIV-1 RNA and (B) final CD4 cell counts by calendar year for 1,814
unique patients tested for both parameters at least once from 1999 through 2011. The number of individuals each year ranged from 575 in 1999 to
854 in 2011. The HIV-1 RNA lower limit of quantitation was 50 copies/mL from 1-1-99 to 10-17-02, 75 copies/mL from 10-18-02 to 3-4-08 and 40
copies/mL from 3-5-08 to 12-31-11.
doi:10.1371/journal.pone.0056845.g001

The Infectious Diseases Laboratory performs the clinical HIV-1
RNA and CD4 cell counts for our medical center. Written consent
was not needed from patients as these tests were performed for
clinical indications and not specifically for research purposes. As a
clinical laboratory, we maintain databases of these test results. For
purposes of the present analyses, we de-identified the datasets.
Because we used de-identified, limited datasets, our medical
center’s IRB deemed this study to be exempt from the board’s
review since it would pose minimal risk for patients’ privacy and
data confidentiality.

Methods
We retrospectively evaluated every HIV-1 RNA and paired
CD4 cell count performed by the Infectious Diseases Laboratory
for all patients tested for both parameters at least once from
January 1999 through December 2011 at the Washington DC
Veterans Affairs Medical Center. This evaluation included all
HIV-infected persons who received care at the clinic without
regard to whether the person was prescribed antiretroviral
therapy. No charts were reviewed.
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Figure 2. Annual and monthly means of HIV-1 RNA and CD4 cell counts. (A) Annual log10-transformed HIV-1 RNA means and CD4 cell count
geometric means calculated from each patient’s final values by calendar year. (B) Monthly log10 HIV-1 RNA means and (C) CD4 cell count geometric
means calculated from all testing in a given month which represented 21–24% of that year’s number of patients (575 persons in 1999 to 854 in 2011).
Two-limit Tobit, censored regression models were used to estimate the true mean log10 HIV-1 RNA values by month and year. CD4 cell counts of 0
were assigned the value of 1 cell/mL.
doi:10.1371/journal.pone.0056845.g002

Although our laboratory performed HIV-1 RNA testing prior to
1999, the lower limit of quantitation for that method was 500
copies/mL and it quantitated 1.5- to 4.5-fold lower than the two
subsequent assays used in this report, Versant HIV-1 RNA 3.0
Assay (bDNA) (Siemens Healthcare Diagnostics Inc., Tarrytown,
NY) and Abbott RealTime HIV-1 (Abbott Molecular Inc., Des
Plaines, IL). These latter assays produced equivalent results in the
quantitative range [18]. For CD4 cell count determinations,
leukocyte counts were obtained from a hematology analyzer, and
the percent lymphocytes and %CD4+ T-lymphocytes were
analyzed by flow cytometry [19] using a FACSCalibur or
FACSCanto II flow cytometer (BD Biosciences, San Jose, CA).
The leukocyte count, percent lymphocytes and %CD4+ Tlymphocytes were then multiplied to calculate the CD4 cell count.
HIV-1 RNA data were transformed using base-10 logarithms.
In order to minimize bias, two-limit Tobit, censored regression
models (Supporting Information, [20]) were used to estimate the
true mean log10 values by month and year: simple substitutions of
the censored data with one-half of the lower limit of quantitation
(LLOQ) or with the fill-in value method exhibit bias when the
percentage of measurements ,LLOQ reach 5–10% and 30%,
respectively [21]. Because CD4 cell counts were positively skewed,
these data were also transformed by using base-10 logarithms.
Arithmetic means of the log10-transformed CD4 cell counts were
calculated by month and year. These means were then back
transformed to obtain the geometric means.
For both HIV-1 RNA and CD4 cell counts, polynomial
regression models were fitted to their 156 monthly means to
determine the trends. Residual plots were used to visually assess
whether model assumptions were satisfied. In addition, the
correlation properties of the residuals were analyzed using the
identification stage of the Box-Jenkins approach to autoregressive
integrated moving average (ARIMA) modeling [22]. Ljung-Box
chi-square statistical tests were applied to test the null hypothesis
that the set of autocorrelations was white noise; there was no
information in the series to model, and no ARIMA model was
needed for the series. The autocorrelations were checked in groups
of six up to 24 lags. All statistical analyses were performed using
SASH software, Version 9.2 (SAS Institute, Cary, NC).

Discussion
This evaluation demonstrates the profound impact on the course
of HIV that can be achieved in a broadly diverse inner-city clinic.
From the beginning of our observation period in 1999, HIV-1 viral
loads improved remarkably such that 72% of our patients measured
below the lower limit of quantitation by the end of 2011.
Importantly, CD4 cell counts also improved such that 89% of our
patients had $200 cells/mL by the end of 2011, above the generally
recognized threshold for opportunistic infections [23]. Furthermore,
our data includes information on persons who were not prescribed
antiretroviral treatment based on CD4 cell count or patientcentered issues. Therefore, despite inclusion of these persons in the
analysis, the viral burden of the overall clinic population markedly
decreased over the 13 years of this evaluation. These gains are
particularly meaningful given patients’ significant barriers to success
[3–17]. In our clinic, more than half of our veterans have major
medical, mental health or substance abuse issues.
Our study has the advantage of using a complete data set from a
single inner-city setting to provide comprehensive trends for HIV1 viral loads and CD4 cell counts within the same observation
period and include data through 2011. Earlier analyses focused
solely on viral loads [24–26] or CD4 cell counts [27],[28]. A recent
publication [29] did analyze HIV-1viral loads and CD4 cell count
trends for multiple U.S. sites through 2008 and examined median
CD4 cell counts only at death. Our data on viral loads can be
compared to the information on antiretroviral therapy in the
Medical Monitoring Project in United States during 2008–2010
[30]. When using viral suppression as defined by a viral load of
,200 copies/mL, 79% of our patients met this criterion, which
was comparable to the estimated 77% of persons with HIV
suppression in the Medical Monitoring study. However, this study
did not include CD4 count monitoring.
The advantages of multidisciplinary teams providing medical
and psychosocial support have been documented [14],[31].
Integrated care, pharmacists’ assistance, co-location of mental
illness services, and psychosocial well-being have been important
in retention to care [32–35], as more HIV-infected veterans
reported a lower quality of life compared to non-infected veterans
[36]. Our findings highlight that incorporating these approaches
to HIV care, can help patients attain the benefits of highly effective
antiretroviral treatment. Another valuable tool for us has been the
robust electronic medical record of the Veterans Affairs healthcare
system that allows the quick review of medication renewals in
order to uncover adherence issues during clinic visits.
In conclusion, our clinic patients attained striking improvements
in HIV-1 RNA suppression and CD4 cell counts from 1999
through 2011, demonstrating that these goals can be realistically
achieved for most individuals in clinical care.

Results
For 1,814 unique individuals, ranging from 575 persons in 1999
to 854 persons in 2011, there were a total of 25,678 HIV-1 RNA
and 24,992 CD4 cell counts performed. As seen in Figure 1A,
based on each patient’s final value of the year, the percentage of
patients with viral loads below the lower limit of quantitation rose
from 29% in 1999 to 72% in 2011 (Table S1), while the
percentage with CD4 counts ,200 cells/mL fell from 31% to 11%
during that same period of time (Figure 1B and Table S2). On
average annually, the mean HIV-1 RNA decreased by 86 copies/
mL and the mean CD4 counts increased by 16 cells/mL
(Figure 2A). For the monthly means, the correlations (R2) were
0.944 for log10 HIV-1 RNA (Figure 2B) and 0.840 for CD4 cell
counts (Figure 2C).
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